Instead of celebrating VIVUS' (NASDAQ:VVUS) drug launch last quarter, shareholders were shocked to hear the company report thin sales and see the stock's share price cut by a whopping 20%. The company is set to report its fourth-quarter results -- the first full quarter featuring Qsymia sales -- on Feb. 25, and investors are wondering whether this biotech can regain its momentum. Should they continue tracking sales, or are there other issues that deserve equal attention? Health-care analyst Max Macaluso dives into this topic in the following video.
Motley Fool Returns
Stock Advisor S&P 500
Stock Advisor launched in February of 2002. Returns as of 01/25/2020.Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return